A drug molecule doesn’t have to be new to get patent protection.
That statement sounds counterintuitive in an industry built on discovering novel chemical entities, but it describes a potential value-creation strategy in pharmaceutical development. Taking an existing drug with an established safety profile and giving it a new indication, delivery mechanism, or dosing schedule can, in some cases, generate a new drug product. However, for that drug product to be commercially viable, it may need its own intellectual property. The catch is that identifying patentable opportunities can be a complicated process. Whether a new formulation can generate IP comes down to whether it addresses a meaningful challenge and whether its solution is legally considered non-obvious. Importance of Patent Protection for New Uses of Existing Drugs
New chemical entities (NCEs), genuinely novel drug substances, receive patent protection for roughly 20 years from filing. The exclusivity provided by patent protection is what makes the economics of drug development work considering the costs associated with the whole process and risk of failure.
An existing drug being developed for a new use starts from a very different position. While the risks of failure are lower, there is still a significant investment needed to bring the drug through development and clinical trials. However, because the NCE is already known, it cannot be patented. Patent protections based on the method of using the drug (for example, a new indication) are difficult to enforce compared to patents with compositional claims. The drug product manufacturer could legally produce the existing product that supplies markets for both the original and new indication. On the other hand, if a new formulation is required for the new indication, and that new formulation is patented, it could not be produced by a rival company for the full patent term without infringing the patent.
The Playbook in Action: Pfizer’s Procardia XL
One of the clearest illustrations of this strategy predates the current wave of reformulation activity by decades: Pfizer’s Procardia XL, widely regarded as the company’s first blockbuster drug.
Nifedipine, the active ingredient, was already an established treatment for angina and hypertension in its original immediate-release form, meaning patients had to take it multiple times a day, with the peaks and troughs in blood concentration that come with frequent dosing. The molecule itself was not new, and it was not going to earn Pfizer a fresh 20-year patent.
What was new was the delivery system. By reformulating nifedipine using Alza’s OROS osmotic pump technology (a semi-permeable membrane design that releases the drug at a steady, controlled rate as fluid is drawn into the tablet), Pfizer converted a multiple-times-daily medication into a true once-daily product. This improvement in dosing frequency provided a meaningful clinical benefit and the drug delivery technology specifically developed for the drug represented a patentable formulation invention. The formulation and delivery technology, not the underlying nifedipine molecule, became the protected asset, and it was enough to build a blockbuster franchise on a drug substance that already existed.
Procardia XL is far from an isolated case. The same underlying logic (extended-release systems, new routes of administration, and pH- or site-targeted delivery) has supported new formulation patents on drugs from methylphenidate to diclofenac to budesonide, decades after their original chemical entities first went off-patent.
The Regulatory Path Runs Alongside the IP Strategy
In the U.S., many of these reformulated products move through the FDA’s 505(b)(2) pathway, which allows an application to rely in part on existing safety and efficacy data for the drug substance rather than generating the full data package required of a new molecule. That materially lowers development cost and risk compared with an NCE program, but it does not, by itself, create patent protection. The IP still has to come from something genuinely novel in the formulation, the delivery mechanism, or the approved use.
This is exactly why the two workstreams, regulatory strategy and formulation science, have to move together from the earliest stages of a reformulation project. A change in dosing-frequency or new delivery system that isn’t rigorously characterized, isn’t stable, and isn’t well-differentiated from the original product is unlikely to support a defensible patent claim, no matter how favorable the regulatory pathway looks on paper.
The Strategic Takeaway
New formulations of existing drugs can absolutely generate new, valuable intellectual property, but the formulation has to earn it. A modest tweak to an existing product is unlikely to clear that bar; a genuinely novel delivery system, release profile, or dosing regimen, one that’s backed by solid analytical and stability data, has a real shot at both regulatory approval and a defensible patent position.
That’s the point where formulation science, analytical testing, and stability work stop being a checkbox on the way to filing and start being the foundation of the IP itself. For companies evaluating whether an existing drug substance has another product left in it, the earliest and highest-leverage question isn’t “can we get this approved?” It’s “what can we prove is genuinely novel about how we’re delivering it?”
If your team is exploring a new formulation, delivery system, or indication for an existing drug substance and wants to understand what’s scientifically achievable and legally defensible, FreeThink’s formulation development and analytical teams can help assess the path from concept to a stable, differentiated product supported by a sound patent strategy.
Sources consulted: Pfizer product labeling for Procardia XL (nifedipine extended-release tablets); The Pharmaceutical Journal, “Research and development in oral controlled release drug formulations”; DrugPatentWatch analysis of 505(b)(2) reformulation strategy and case examples (Concerta, Pennsaid 2%, Uceris, Colcrys).